Fig. S1. Flow chart demonstrating sample utilization for different analysis.

Fig. S2. Expression pattern of estrogen and progesterone receptors in breast cancer of Indian patients.

Fig. S3. Alteration patterns of Wnt/β-catenin antagonists in stage I and II/III and IV and Grade I and I/III breast cancer.

Table S1. Summary of oligonucleotides.

Table S2. Antibodies and conditions used for immunohistochemical analyses.

Table S3. Alteration patterns of Wnt/β-catenin antagonists and β-catenin in breast cancer.

Table S4. Association of deletion between Wnt/β-catenin antagonists in breast cancer samples.

Table S5. Association of promoter methylation between Wnt/β-catenin antagonists in breast cancer.

Table S6. Clinicopathological correlation of the alterations (deletion and methylation) of Wnt/β-catenin antagonists in breast cancer.

Data S1. Additional methods including: sample collection and clinical data; microdissection and DNA extraction; deletion analysis; promoter methylation analysis; expression analysis by immunohistochemistry; and statistical analysis.

CAS_2131_sm_DataS1.doc44KSupporting info item
CAS_2131_sm_fS1.jpg550KSupporting info item
CAS_2131_sm_fS2.jpg156KSupporting info item
CAS_2131_sm_fS3.tif7855KSupporting info item
CAS_2131_sm_tS1.doc53KSupporting info item
CAS_2131_sm_tS2.doc42KSupporting info item
CAS_2131_sm_tS3.xls96KSupporting info item
CAS_2131_sm_tS4.doc93KSupporting info item
CAS_2131_sm_tS5.doc89KSupporting info item
CAS_2131_sm_tS6.doc55KSupporting info item

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.